Home > Insider Trading > Filing (0000899243-21-018121)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1785530	Werewolf Therapeutics Inc.	HOWL	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1321178	Moshe Arkin	6 Hachoshlim St. Herzelia L3 4672406	No	No	Yes	No
1858705	L.p. 2 Ventures Bio Arkin	6 Hachoshlim Street Herzliya Pituach L3 4672406	No	No	Yes	No
1858707	Ltd. Gpgp Ventures Bio Arkin	6 Hachoshlim Street Building C Herzliya Pituach L3 4672406	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-05-04	1,235,917	$0.00	1,235,917	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-05-04	410,717	$0.00	1,646,634	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2021-05-04	400,000	$16.00	2,046,634	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2021-05-04	10,714,284	$0.00	1,235,917	$0.00
Common Stock	Series B Preferred Stock	Disposition	2021-05-04	3,560,551	$0.00	410,717	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

On May 4, 2021, the Series A Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
The securities are held by Arkin Bio Ventures 2 L.P. (the "Fund"). The general partner of the Fund is Arkin Bio Ventures GP, the general partner of which is Arkin Bio Ventures GPGP Ltd. Moshe Arkin is the sole shareholder and chairman of the board of Arkin Bio Ventures GPGP Ltd. As a result, each of Arkin Bio Ventures GP, Arkin Bio Ventures GPGP Ltd. and Mr. Arkin may be deemed to share voting and investment power with respect to the shares held by the Fund.
On May 4, 2021, the Series B Preferred Stock automatically converted into Common Stock on a 8.6691-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.